Eurofins Fact Sheet
Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. The Group believes it is the world leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
Eurofins Scientific was founded in 1987 with 4 employees to market the SNIF-NMR® technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.
Today the Eurofins Group is a leading provider of analytical services with :
- an international network of more than 400 laboratories across 44 countries in Europe, North and South America and Asia-Pacific
- over 35,000 staff
- a portfolio of over 150,000 analytical methods
- more than 360 million tests performed each year to establish the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as carry out human diagnostic services.
Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins' sales have increased by 36% each year (in compound average) to over EUR 2.97 billion in 2017.
Between the Initial Public Offering on 24 October 1997 (€1.83) and 29 December 2017 (€507.60), Eurofins’ share price has multiplied by 277x, an annual average increase of 32% (against 4% for the SBF 120, 3% for the CAC 40 and 7% for the Nasdaq over the same period).
In 2015, Eurofins achieved its mid-term objective set in 2012 of generating EUR 2bn annual revenues by 2017, two years early, with EUR 2.24bn pro-forma revenues in 2015 (EUR 1.95bn on a reported basis). The Group’s ability to execute on its mid-term plan reflects the benefits of both past and ongoing investments to put together the most comprehensive portfolio of analytical methods and the most modern, state-of-the-art laboratory network that allows the Group to provide best-in-class analytical services to the markets it serves in the most efficient manner. Having consistently invested at higher rate than any of its large peers in the testing industry, Eurofins boasts a very modern, streamlined network of laboratories uniquely capable of providing high quality analyses at a reasonable cost. In 2017 alone, the Group added another 53,000m2 of world class laboratory surface to its network, and plans another 189,000m2 additional capacity between 2018 and 2019, to bring total modernized laboratory surface to over 600,000m2.
Over the years, Eurofins has developed many new analytical testing methods and has participated in, or led several R&D projects to find better ways to analyse food, the environment, and pharmaceutical products. More recently, the Group has also started to leverage its world-renowned genomics expertise in the area of specialty clinical diagnostics testing to provide new human diagnostic capabilities. In 2017 Eurofins made very good progress towards its operational objectives for 2020 of building an unmatched state-of-the-art global laboratory infrastructure in its markets. A record number of acquisitions were also completed throughout the year and 30 start-up laboratories launched. Thanks to this and continued strong organic growth above peers, Eurofins has exceeded its recently-upgraded 2017 objectives of delivering reported revenues in excess of EUR 2.9bn and EUR 3.35bn on a pro-forma basis. Eurofins has achieved four new leadership positions in its markets in 2017: global leadership position in discovery pharmacology, in genomics services and in agroscience CRO services, and European leadership position in forensics services. Additionally, Eurofins has also created three new significant business lines in 2017: Eurofins entered the dynamic and growing pharmaceutical contract development and manufacturing organization (CDMO) market and also entered the growing advanced materials sciences market. Eurofins also reinforced its position in the clinical genetics market with additional non-invasive prenatal testing (NIPT) capabilities.
Eurofins is committed to supporting its clients’ objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate and supporting medical practitioners and patients with innovative diagnostic services. The Group intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
In March 2018, Eurofins’ management raised once again its objectives for 2018, from annual revenues of EUR 3.6bn to EUR 3.7bn, and set its adjusted EBITDA objective to EUR 700m in 2018. Underlying trends remain positive across the Group’s businesses, and Eurofins’ management believes that the Group is on track to achieve its recently-upgraded mid-term objective of reaching EUR 4bn revenues by 2019. Should this be achieved, Eurofins would have doubled in size once again in only 4 years.
|Contact and Addresses|
Florian Heupel, Group Marketing